combining glp-1 receptor agonist with dpp-4 inhibitor not recommended guideline DPP4 Inhibitors vs Agonists | June 2021 | Clinical Corner Mechanism of action of GLP-1
Description
Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes
Gastrointestinal symptoms dominate
?, unknown
While GLP-1 drugs may offer neuroprotective effects relevant to glaucoma, the impact of dual-incretin therapies like tirzepatide on glaucoma remains unknown
If appropriate, they'll prescribe a medication that suits you
Normally when you eat, this triggers the release of GLP-1 and signals are sent to the brain telling it you are full, so you stop eating
